OBI Pharma, Inc.
From Wikipedia, the free encyclopedia
Native name | 台灣浩鼎生技股份有限公司 |
|---|---|
Company type | Public |
| TWSE: 4174(TPEx) | |
| Industry | Pharmaceuticals |
| Founded | 2002 |
| Headquarters | 6F, No. 508, Sec. 7, Zhongxiao E RdNangang District, Taipei City, 115, Taiwan |
Key people | Kung-Yee Liang (Chairman) Ya-Chi Chen (CEO) |
| Website | www.obipharma.com |
OBI Pharma, Inc. (Chinese: 台灣浩鼎生技股份有限公司) (TWSE: 4174) is a bio-pharmaceutical company, based in Nangang District, Taipei, Taiwan.[1][2]
In 2018 it announced that its drug, OBI-3424, has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA) for the treatment of Hepatocellular Carcinoma (HCC).[3]
The company was founded by Micheal N.Chang on April 29, 2002.[4] It was formerly a subsidiary of Optimer Pharmaceuticals.
On 9 Feb 2007, its parent company Optimer Pharmaceuticals can buy/sell on Nasdaq Stock Exchange. At that time, its share price was US$8.50 per share.
On 15 May 2012, OBI Pharma, Inc. was approved to become a public company in Taiwan.
On 23 Mar 2015, it can do transaction formally on OTC in Taiwan R.O.C.
On February 8, 2022: OBI Pharma (4174.TWO) announced the development of its COVID-19 vaccine, BCVax.
2023, BCVax received approval from Taiwan’s Food and Drug Administration (TFDA) for a Phase I clinical trial.
2023, Anticancer drug OBI-3424 was approved by TFDA for a Phase II clinical trial. In the same year, OBI Pharma developed its proprietary ADC platforms, including a cysteine-based conjugation platform and GlycOBI™.
2023, OBI Pharma obtained ISO/IEC 27001 certification for information security management.
2023, OBI Pharma and its subsidiary, OBIGEN Pharma Biotech, signed an exclusive global medical use license agreement for OBI-858.
2023, OBI Pharma signed a licensing agreement with Ablexis, LLC for the global rights to the "Nectin4 human antibody sequence."
On December 29, 2023: Kung-Yee Liang succeeded as Chairman of OBI Pharma.[5]
On January 31, 2024: The Phase III trial of Adagloxad Simolenin (OBI-822) and OBI-821 for triple-negative breast cancer completed its first interim analysis, with the Data and Safety Monitoring Board (DSMB) recommending continuation.
On March 11, 2024: OBI Pharma’s board decided to halt patient enrollment in the OBI-3424 Phase II trial, while collaboration with international partners continued.[6]
On June 12, 2024: OBI-992, a TROP2-targeted ADC, received U.S. FDA approval for a Phase I/II clinical trial to evaluate its safety and efficacy in solid tumors.[7]
On August 7, 2024: OBI-992 was granted U.S. FDA orphan drug designation for gastric cancer, including gastroesophageal junction adenocarcinoma.[8]
On September 24, 2024: OBI-992 was shortlisted for the "2024 Most Promising Clinical Candidate" at the 11th World ADC Awards.[9]
On October 13, 2024: OBI Pharma’s partner, Ascentawits (Shenzhen), presented Phase II interim results for AST-3424 (OBI-3424) at the CSCO meeting, receiving an "Outstanding Paper Award."[10]
On December 11, 2024: OBI Pharma received the Sports Enterprise Certification from Taiwan’s Ministry of Education for the second time.[11]
On December 23, 2024: OBI Pharma signed marketing and material transfer agreements with Japan’s GlyTech to promote GlycOBI® ADC technology in Japan’s biopharma industry.[12]
On March 12, 2025: OBI Pharma won the "Most Promising ADC Clinical Candidate in Taiwan" award at the ADC Asia Congress 2025 in Singapore.[13]
On March 18, 2025: OBIGEN Pharma, an OBI Pharma subsidiary, appointed OBI Pharma CEO Heidi Wang as Chairman, succeeding Frank Chen, who resigned.[14]
On March 26, 2025: OBI Pharma received the "Most Promising Immunotherapy Pipeline" award from the Taiwan Bio-Excellence Awards (TBEA).[15]
On April 30, 2026: Dr. Ya-Chi Chen, Chief Scientific Officer of OBI Pharma, assumed the role of Acting Chief Executive Officer.
Primary Focus
The company mainly concentrates on the development of the research and development of cancer therapies and high-quality drugs.[16]
References
- ↑ "OBI Pharma signs cancer drug deal with HK's Odeon - Taipei Times". www.taipeitimes.com. 2022-02-24. Retrieved 2024-04-19.
- ↑ "Odeon Therapeutics acquires China rights to two cancer therapy candidates from Obi Pharma in $200M deal | BioWorld". www.bioworld.com. Retrieved 2024-04-19.
- ↑ "FDA grants ODD to OBI Pharma's lead investigational drug candidate". www.biospectrumasia.com. Retrieved 2024-04-19.
- ↑ "OBI Pharma Inc. Company & People | 4174". Barron's. Retrieved 2024-02-20.
- ↑ "The Company's Board of Directors nominated Dr. Kung-Yee Liang to serve as the Chairperson of the Board". OBI Pharma 台灣浩鼎. Retrieved 2025-03-27.
- ↑ "OBI announces the termination of OBI-3424 Phase II trial". OBI Pharma 台灣浩鼎. 2024-03-11. Retrieved 2025-03-27.
- ↑ "OBI Pharma announces Phase 1/2 study initiation for OBI-992, a TROP2-targeted antibody drug-Conjugate (ADC) for cancer therapy". OBI Pharma 台灣浩鼎. 2024-06-12. Retrieved 2025-03-27.
- ↑ "OBI-992 has been approved by US FDA for Orphan Drug Designation for the treatment of gastric cancer". OBI Pharma 台灣浩鼎. 2024-08-07. Retrieved 2025-03-27.
- ↑ "OBI-992 Shortlisted as the Most Promising Clinical Candidate in the 11th Annual World ADC Awards". OBI Pharma 台灣浩鼎. 2024-09-24. Retrieved 2025-03-27.
- ↑ "Ascentawits Pharma announced the interim analysis results of the AST-3424 Phase II clinical efficacy and safety study in advanced HCC at the 2024 CSCO conference". OBI Pharma 台灣浩鼎. 2024-10-13. Retrieved 2025-03-27.
- ↑ "OBI Pharma Earns Sports Enterprise Certification Again Building a Healthy Workplace and Fulfilling Sustainability Commitments". OBI Pharma 台灣浩鼎. 2024-12-11. Retrieved 2025-03-27.
- ↑ "OBI Pharma Enters Collaboration with GlyTech to Expand GlycOBI® Enabling Technologies Outreach in Japan and to Advance Glycan Production". OBI Pharma 台灣浩鼎. 2024-12-23. Retrieved 2025-03-27.
- ↑ "OBI Pharma Receives 'Most Promising ADC Clinical Candidate in Taiwan' Award Dr. Heidi Wang Accepts Award on Behalf of OBI Pharma at ADC Asia Congress 2025 and Gives a Presentation". OBI Pharma 台灣浩鼎. 2025-03-12. Retrieved 2025-03-27.
- ↑ "New Chairman of OBIGEN Pharma: OBI Pharma CEO Heidi Wang Takes Over". OBI Pharma 台灣浩鼎. 2025-03-18. Retrieved 2025-03-27.
- ↑ "OBI Wins " Most Promising Immunotherapy Pipeline" Award Showcasing TROP2 ADC Research at Biologics World Taiwan". OBI Pharma 台灣浩鼎. 2025-03-26. Retrieved 2025-03-27.
- ↑ "OBI Pharma, Inc | LinkedIn". www.linkedin.com. Retrieved 2024-02-20.